Modality
Bispecific Ab
MOA
PI3Ki
Target
LAG-3
Pathway
PD-1/PD-L1
ADHDParkinson's
Development Pipeline
Preclinical
~Mar 2019
→ ~Jun 2020
Phase 1
Sep 2020
→ Jan 2028
Phase 1Current
NCT03118813
309 pts·Parkinson's
2020-09→2028-01·Completed
309 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-01-281.8y awayPh2 Data· Parkinson's
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
P1/2
Complet…
Catalysts
Ph2 Data
2028-01-28 · 1.8y away
Parkinson's
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03118813 | Phase 1/2 | Parkinson's | Completed | 309 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 |